This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Pediatrics  • Neonatology and Infant Care  • Alert me on articles by topic

JAMA. 2007;298:1390-1392.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2007;56:701-705

2 figures, 1 table omitted

Group B streptococcus (GBS) is a leading cause of neonatal morbidity and mortality in the United States. In 2002, CDC, the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Pediatrics (AAP) issued revised guidelines for the prevention of perinatal GBS disease. These guidelines recommend universal screening of pregnant women by culture for rectovaginal GBS colonization at 35-37 weeks' gestation and the use of intrapartum antibiotic prophylaxis for GBS carriers.¹ To examine rates of neonatal and pregnancy-associated GBS disease after the revised guidelines were issued, CDC analyzed surveillance data from the Active Bacterial Core surveillance (ABCs) system from the period 2003-2005 and compared them with data from 2000-2001, the period immediately preceding the universal screening recommendations. This report describes the results of that analysis, which indicated that annual incidence of early onset GBS disease (i.e., in infants aged 0-6 days) . . . [Full Text of this Article]

Reported by: